Roche (Genentech) entered into a $1 billion deal with NewLink Genetics, a company with an IDO (indoleamine 2,3-dioxygenase) inhibitor. Continue reading
![](https://blogs.shu.edu/cancer/files/2014/06/seal.png)
Roche (Genentech) entered into a $1 billion deal with NewLink Genetics, a company with an IDO (indoleamine 2,3-dioxygenase) inhibitor. Continue reading